Literature DB >> 22162582

Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.

Paul A Clarke1, Paul Workman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22162582     DOI： 10.1200/JCO.2011.38.7167

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  18 in total

1.  Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.

Authors:  Ashish A Kulkarni; Bhaskar Roy; Poornima S Rao; Gregory A Wyant; Ayaat Mahmoud; Madhumitha Ramachandran; Poulomi Sengupta; Aaron Goldman; Venkata Ramana Kotamraju; Sudipta Basu; Raghunath A Mashelkar; Erkki Ruoslahti; Daniela M Dinulescu; Shiladitya Sengupta
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

Review 2.  Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.

Authors:  Hashem A Dbouk; Jonathan M Backer
Journal:  Trends Pharmacol Sci       Date:  2013-02-12       Impact factor: 14.819

Review 3.  Emerging biomarkers in head and neck cancer in the era of genomics.

Authors:  Hyunseok Kang; Ana Kiess; Christine H Chung
Journal:  Nat Rev Clin Oncol       Date:  2014-11-18       Impact factor: 66.675

4.  The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.

Authors:  Lilian Amrein; May Shawi; Jeremy Grenier; Raquel Aloyz; Lawrence Panasci
Journal:  Int J Cancer       Date:  2013-01-15       Impact factor: 7.396

Review 5.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

Review 6.  Discovery and development of small molecule SHIP phosphatase modulators.

Authors:  William G Kerr; John D Chisholm; Dennis R Viernes; Lydia B Choi
Journal:  Med Res Rev       Date:  2013-12-02       Impact factor: 12.944

7.  The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

Authors:  Craig P Carden; Adam Stewart; Parames Thavasu; Emma Kipps; Lorna Pope; Mateus Crespo; Susana Miranda; Gerhardt Attard; Michelle D Garrett; Paul A Clarke; Paul Workman; Johann S de Bono; Martin Gore; Stan B Kaye; Udai Banerji
Journal:  Mol Cancer Ther       Date:  2012-05-03       Impact factor: 6.261

8.  First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Authors:  Debashis Sarker; Joo Ern Ang; Richard Baird; Rebecca Kristeleit; Krunal Shah; Victor Moreno; Paul A Clarke; Florence I Raynaud; Gallia Levy; Joseph A Ware; Kathryn Mazina; Ray Lin; Jenny Wu; Jill Fredrickson; Jill M Spoerke; Mark R Lackner; Yibing Yan; Lori S Friedman; Stan B Kaye; Mika K Derynck; Paul Workman; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2014-11-04       Impact factor: 12.531

Review 9.  Discovery of small molecule cancer drugs: successes, challenges and opportunities.

Authors:  Swen Hoelder; Paul A Clarke; Paul Workman
Journal:  Mol Oncol       Date:  2012-03-03       Impact factor: 6.603

10.  Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.

Authors:  Joo Ern Ang; Rupinder Pandher; Joo Chew Ang; Yasmin J Asad; Alan T Henley; Melanie Valenti; Gary Box; Alexis de Haven Brandon; Richard D Baird; Lori Friedman; Mika Derynck; Bart Vanhaesebroeck; Suzanne A Eccles; Stan B Kaye; Paul Workman; Johann S de Bono; Florence I Raynaud
Journal:  Mol Cancer Ther       Date:  2016-04-05       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.